You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
4 October 2024
26 July 2024
Merck KGaA: Strong 2nd Quarter, Guidance raised
24 June 2024
Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
23 May 2024
21 May 2024
16 May 2024
18 November 2024
Q3 statement / Q3 financial report 2024
8 August 2024
Half-yearly financial report 2024
15 May 2024
Q1 statement / Q1 financial report 2024
13 August 2009
Original-Research: Merck KGaA (von GBC AG):
